Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 52Observational 2Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 1

Interventions

gallium 68 PSMA-11 4Magnetic Resonance Spectroscopy 4Abiraterone Acetate 3carbon-11 acetate 2Prednisone 2Prednisolone 2Axitinib 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2zenocutuzumab 1ulixertinib 1trametinib 1tempol 1tazemetostat 1talazoparib 1radium Ra 223 dichloride 1pegilodecakin 1omburtamab I-131 1niraparib 1neratinib 1motexafin gadolinium 1enfortumab vedotin 1dodecyl maltoside 1bicalutamide 1bemarituzumab 1balstilimab 1atezolizumab 1apalutamide 1TEMPOL-H 1Suspensions 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × enfortumab vedotin × Genitourinary × Clear all
NCT04136808 2020-01-13

An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Astellas Pharma Inc

Approved for marketing
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡